Krystal Biotech (KRYS) Stock Forecast & Price Target

Krystal Biotech reported a significant increase in net Vyjuvek revenue, achieving $389.1 million for FY25, up from $290.5 million in FY24, indicating robust growth and market penetration, particularly with recent expansions into Germany. The company is experiencing positive demand metrics and anticipates ongoing revenue growth driven primarily by international sales, as management focuses on expanding into community settings in the U.S. Furthermore, the clinical progress of KB407, demonstrating favorable pharmacokinetics and potential for repeat dosing, strengthens the company's position in the cystic fibrosis market, suggesting additional opportunities for growth and improved patient compliance.

Krystal Biotech reported a gross margin of 94% for 4Q25, although net income decreased to $51.4 million from $79.4 million in the prior quarter, raising concerns about financial stability in the short term. The company faces significant challenges, including the risks associated with clinical trials, potential funding inadequacies, and the inherent unpredictability tied to the development of gene therapies, which could jeopardize the success of its pipeline beyond Vyjuvek. Furthermore, competitive pressures and the rarity of the diseases being targeted may hinder patient recruitment, posing additional risks to the company’s long-term growth and market positioning.